| Value | ₹4.17 Cr |
|---|
BSE filing, NSE: SHUKRAPHAR. Summary written from the filing by ALFA Finder's alert engine.
Shukra Pharmaceuticals Ltd: key numbers
- Share price
- ₹79.88
- Market cap
- ₹3,535 Cr
- Revenue (annual)
- ₹56.73 Cr
- Net profit (annual)
- ₹22.06 Cr
- P/E (TTM)
- 104.0×Sector 41.3×
- Promoter holding
- 51.15%+0.19% QoQ
- FII holding
- 0.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shukra Pharmaceuticals Ltd
All →Shukra Pharmaceuticals Board Meeting Date
Shukra Medtech Limited has scheduled a board meeting on November 3, 2026, to consider and approve its unaudited financial results for the quarter ended September 2026.
Shukra Pharmaceuticals Other Announcement
Shukra Medtech submitted a revised CA certificate to NSE for its name and symbol change application. The filing requests final exchange approval for the corporate rename.
Shukra Pharmaceuticals Other Announcement
Shukra Pharmaceuticals Limited has submitted the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Shukra Pharmaceuticals Capital Structure Change
Shukra Pharmaceuticals allotted 17.35 lakh equity shares upon warrant conversion to promoters. The exercise raised Rs. 4.63 Crore, increasing the paid-up capital.
- Value
- ₹4.63 Cr
Shukra Pharmaceuticals Price Movement Clarification
Shukra Pharmaceuticals clarified that the recent share price movement is market-driven. The company confirmed no undisclosed, price-sensitive information exists.
Shukra Pharmaceuticals Annual General Meeting
Shukra Pharmaceuticals Ltd issued a corrigendum to its Postal Ballot notice regarding the proposed alteration of its Main Object Clause and name change.
Other debt & borrowing announcements
All →Amines & Plasticizers Debt & Borrowing
Amines & Plasticizers invited members to place unsecured deposits under Form DPT-1. Only resident members may subscribe, and the scheme is on the company website.
HEG Advanced Materials Debt & Borrowing: ₹50 Cr
HEG granted subsidiary Replus Engitech an unsecured revolving loan of Rs.50 Crore. It is repayable on demand at 9% interest, at arm's length.
- Value
- ₹50.00 Cr
- Execution
- Repayable on demand
Purple Finance Debt & Borrowing: ₹25 Cr
Purple Finance's finance committee approved issuing up to 25,000 senior secured NCDs aggregating ₹25 Crore on a private placement basis. The debentures carry an 11.50% coupon and a 30-month tenure.
- Value
- ₹25.00 Cr
- Execution
- 30 months from deemed date of allotment
Bloom Industries Debt & Borrowing: ₹113 Cr
Bloom Industries approved pledging 9.40% of Shivom Minerals shares to secure ₹113 Crore NCDs and convened an EGM. The company states no material adverse operational impact.
- Value
- ₹113.0 Cr
Maxvolt Energy Industries Debt & Borrowing: ₹0.6 Cr
Maxvolt Energy Industries has entered a loan agreement lending up to Rs. 60 Lakhs to its subsidiary Maxvolt Reearth Private Limited. The unsecured facility carries interest of up to 12% over a maximum tenor of 10 years.
- Value
- ₹0.60 Cr
- Execution
- Maximum tenor of 10 years from the Effective Date
Mufin Green Finance Debt & Borrowing: ₹0.47 Cr
Mufin Green Finance paid Rs 0.47 Crore monthly interest on secured NCDs on 3 November 2026. The payment relates to the Rs 50 Crore issue.
- Value
- ₹0.47 Cr